Subscribe
shutterstock_1174421515_eyesonmilan
eyesonmilan / Shutterstock.com
22 August 2019Americas

Gilead challenges US govt patents on HIV drug Truvada

Gilead Sciences, the maker of HIV drug Truvada (emtricitabine/tenofovir), has asked the US Patent and Trademark Office (USPTO) to review patents granted to the government covering preventative use of the drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead fails to have US government patents invalidated
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead fails to have US government patents invalidated
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.

More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead fails to have US government patents invalidated
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.

More features

BMS notches legal win and FDA nod
AstraZeneca fends off diabetes generic, for now
Patent pledges in global crises: Why Moderna prevailed over Pfizer/BioNTech
EPO: Biotech innovation strong, while pharma trails behind
LSPN chair: Uncertainty lies ahead for life sciences
UPC issues sweeping injunction against Meril in heart valve case
PierFerd taps pharma and biotech patent expert from Weiss & Arons
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant